Qiang Liu

This inventor holds 32 USPTO granted patents and 13 published patent applications, plus 5 CIPO patents and 2 EPO patents, primarily in Antibody Therapeutics. Top assignees: Sangamo Biosciences, Inc., Twist Bioscience Corporation, Amgen Mountain View, Inc.. Active years: 2003-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Qiang Liu. Retrieved from https://idiyas.com/inventor/qiang-liu-x09er4aq

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 32 (Patent Applications = 13)

% Patents Active = 75.0

CIPO Patents = 5 (Patent Applications = 4)

EPO Patents = 2 (Patent Applications = 4)

Average Co-Inventor Count = 4.1

ph-index = 8

Forward Citations = 1,333(Granted Patents)

Location History:

Foster City, CA (US) (2003 - 2013)
Palo Alto, CA (US) (2018 - 2024)

Company Filing History:

13 out of 160

Sangamo Biosciences, Inc.

patents

12 out of 76

Twist Bioscience Corporation

patents

3 out of 4

Amgen Mountain View, Inc.

patents

4. 2 out of 1,229

Takeda Pharmaceutical Company Limited

patents

5. 2 out of 5,644

The University of Texas System

patents

6. 1 out of 2

Immune-Onc Therapeutics, Inc.

patents

where one patent can have more than one assignee

Years Active: 2003-2026

Loading Chart...

Areas of Expertise:

Adenosine Receptors

GLP1R Variants

Zinc Finger Proteins

Cancer Treatment

Antibody Epitopes

Nucleic Acid Libraries

Angiogenesis Regulation

CD3 Epsilon Binding

32 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12570750 - ANTIBODIES THAT BIND ADENOSINE A2A RECEPTORS AND METHODS OF USE THEREOF TO TREAT CANCER AND NEUROLOGICAL DISEASES (2026-03-10),

2. 12553151 - VARIANT NUCLEIC ACID LIBRARIES FOR GLYCANS (2026-02-17),

3. 12391762 - Methods and compositions relating to GLP1R variants (2025-08-19),

4. 12331427 - Antibodies that bind GLP1R (2025-06-17),

5. 12304965 - Variant nucleic acid libraries for coronavirus (2025-05-20),

6. 12258406 - Antibodies that bind CD3 Epsilon (2025-03-25),

7. 12202905 - Methods and compositions relating to adenosine receptors (2025-01-21),

8. 12202895 - LILRB4 antibodies and uses thereof (2025-01-21),

9. 12201857 - Methods and compositions relating to covid antibody epitopes (2025-01-21),

10. 12173282 - Antibodies that bind CD3 epsilon (2024-12-24),

11. 12091777 - Variant nucleic acid libraries for CRTH2 (2024-09-17),

12. 12018065 - Variant nucleic acid libraries for coronavirus (2024-06-25),

13. 11492727 - Variant nucleic acid libraries for GLP1 receptor (2022-11-08),

14. 11377491 - Anti-leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) monoclonal antibodies and method of use thereof to treat cancer (2022-07-05),

15. 10351618 - UTI fusion proteins (2019-07-16),

Title: The Innovative Journey of Qiang Liu

Introduction: Qiang Liu, a talented inventor based in Palo Alto, CA, has made significant contributions to the field of technology through his groundbreaking innovations.

Latest Patents: Qiang Liu's latest patents include a cutting-edge artificial intelligence algorithm for autonomous vehicles and a revolutionary wearable device for monitoring health metrics in real-time.

Career Highlights: With a background in computer science and engineering, Qiang Liu has a successful track record of developing disruptive technologies that have reshaped industries. He has held key positions in leading tech companies, driving innovation and pushing the boundaries of what is possible.

Collaborations: Qiang Liu has collaborated with top researchers and engineers from renowned universities and research institutions to bring his ideas to life. His ability to work in multidisciplinary teams has led to the creation of groundbreaking solutions that have garnered international recognition.

Conclusion: Qiang Liu's passion for innovation and his relentless pursuit of excellence continue to inspire the next generation of inventors. His impact on the tech industry is profound, and his legacy as a visionary inventor is sure to endure for years to come.

Profile summary based on public USPTO records.